Cerebrolysin: Mechanism, Research Evidence, and Safety

What is cerebrolysin?

Cerebrolysin is an injectable peptide preparation made from purified porcine brain proteins, containing a mix of small peptides and free amino acids.

It is produced by enzymatic digestion of purified pig brain protein into low-molecular-weight fragments (Ziganshina et al., 2023; doi:10.1002/14651858.CD007026.pub7). Researchers group it with neurotrophic-like agents, meaning it is proposed to behave somewhat like the body's own nerve-supporting growth factors. Its regulatory status varies by region: it is used clinically in some health systems and is not approved as a medicine in others. Because it is a peptide mixture, it is not taken by mouth in studies; it is given by injection. On this catalog it is offered for research use only.

How does cerebrolysin work?

Its proposed mechanism is neurotrophic-like activity, meaning it is thought to support neuron survival and repair signaling in ways similar to natural growth factors, though this comes mainly from preclinical work and is not firmly established in humans.

In laboratory and animal models, cerebrolysin has been described as acting on pathways linked to neuron protection, reduced cell death, and support for neuronal plasticity, similar in concept to nerve growth factors (Ziganshina et al., 2023). Human confirmation of a specific mechanism is limited. The clinical reviews below did not establish a mechanism; they measured outcomes. Treat mechanism claims here as proposed rather than proven.

What does the research on cerebrolysin actually show?

The strongest synthesized human evidence, two Cochrane reviews, reports little to no benefit on death or disability in acute stroke and only a low-quality signal of possible short-term cognitive change in vascular dementia.

For acute ischaemic stroke, the most recent Cochrane review pooled randomized trials and found that cerebrolysin (grouped with the similar agent Cortexin) probably results in little to no difference in all-cause death (risk ratio about 0.96; moderate-certainty evidence). It also reported that the total number of people with serious adverse events was similar between groups, but that the number of people with non-fatal serious adverse events was higher with treatment (risk ratio about 2.39, 95% CI 1.10 to 5.23; moderate-certainty evidence). The reviewers flagged that the manufacturer supported several of the multicentre studies, which raises risk of bias (Ziganshina et al., 2023; doi:10.1002/14651858.CD007026.pub7). Reflecting this evidence, a 2021 joint guideline from the European Stroke Organisation and the European Academy of Neurology made a weak recommendation against using cerebrolysin for post-stroke cognitive impairment, while noting the very low quality of the evidence (Quinn et al., 2021; PMID 34476868).

For vascular dementia, a separate Cochrane review of 6 randomized trials in 597 participants reported a beneficial effect on general cognition (mini-mental state examination weighted mean difference about 1.10, 95% CI 0.37 to 1.82), but pointed to small samples, differences between studies, and risk of bias, and concluded there was not sufficient evidence to recommend cerebrolysin as a routine treatment (Chen et al., 2013; doi:10.1002/14651858.CD008900.pub2). A 2019 update found no new eligible trials and reached the same cautious conclusion (Cui et al., 2019; doi:10.1002/14651858.CD008900.pub3). Across both areas, the pattern is mixed and of limited quality.

What dosing has cerebrolysin research reported?

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Trials in the Cochrane reviews gave cerebrolysin by intravenous infusion, with daily amounts reported in the tens of milliliters over courses of roughly two to four weeks. These figures describe what studies administered, not a protocol for anyone.

These figures describe historical study regimens and differed across trials. Cerebrolysin is not an oral supplement; doses in studies were selected and supervised by trial investigators, and there is no self-administration protocol here. Any personal dosing decision belongs with a qualified clinician who can weigh the limited and mixed evidence. This catalog lists cerebrolysin for laboratory research use only.

What are the side effects and safety concerns of cerebrolysin?

Trials often described cerebrolysin as well tolerated, but reported effects include dizziness, headache, sweating, feeling hot, agitation, and injection-site reactions, and its animal-protein origin carries a hypersensitivity risk.

The most recent Cochrane stroke review reported that the total number of people with serious adverse events was similar to control, but that the number of people with non-fatal serious adverse events was higher with treatment (risk ratio about 2.39, 95% CI 1.10 to 5.23), rated as moderate-certainty evidence (Ziganshina et al., 2023; doi:10.1002/14651858.CD007026.pub7). Because cerebrolysin is derived from animal (porcine) brain protein, allergic or hypersensitivity reactions are a recognized concern, and rapid infusion has been linked in the literature to feeling hot or dizzy. Since much of the trial base was manufacturer-supported and of variable quality, all safety conclusions carry limited certainty (Ziganshina et al., 2023).

How does cerebrolysin compare to research peptides like semax and dihexa?

Cerebrolysin is a multi-component peptide mixture given by injection, while semax and dihexa are single-molecule research peptides also studied around cognitive and neurotrophic pathways; there are no strong head-to-head human trials among them.

Cerebrolysin has the largest synthesized human evidence base of the three, though that base is still limited, through the Cochrane reviews in stroke and vascular dementia (Ziganshina et al., 2023; Chen et al., 2013). Semax is a synthetic analog of the ACTH(4-10) fragment (sequence Met-Glu-His-Phe-Pro-Gly-Pro), developed in Russia and registered there as a medicine but not approved by the FDA; it is studied for effects on BDNF signaling, with human data largely limited to Russia and post-Soviet states. Dihexa is an angiotensin-IV-derived peptide studied only in preclinical (animal and cell) models for synapse-related signaling; its proposed mechanism has been contested in the literature, so it is best treated as a working hypothesis, and there are no human efficacy trials. Choosing among them is not an evidence-settled question: they differ in structure, route, and how much human data exists. See the linked hubs for each compound.